Viralkumar Patel

@dsvv.ac.in

Coordinator & Scientist, Yagyavalkya Center for Yagya Research
Dev Sanskriti Vishwavidyalaya

Viralkumar Patel


                  Download Compact PDF  
https://researchid.co/viral.patel

RESEARCH INTERESTS

* Experienced in ancient therapeutic model research, Yagya Research, Herbal Inhalation Therapy,
* Oncology therapeutics research with emphasis on translational medicine
452

Scholar Citations

8

Scholar h-index

7

Scholar i10-index

RECENT SCHOLAR PUBLICATIONS

  • Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy
    VK Patel, B Lamothe, ML Ayres, J Gay, JP Cheung, K Balakrishnan, ...
    Leukemia 32 (4), 920 , 2018
    2018
    Citations: 42
  • Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
    VM Patel, K Balakrishnan, M Douglas, T Tibbitts, EY Xu, JL Kutok, ...
    Leukemia 31 (9), 1872 , 2017
    2017
    Citations: 84
  • Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells
    V Patel, K Balakrishnan, E Bibikova, M Ayres, MJ Keating, WG Wierda, ...
    Clinical Cancer Research 23 (14), 3734-3743 , 2017
    2017
    Citations: 181
  • Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes
    F Cervantes-Gomez, VK Patel, P Bose, MJ Keating, V Gandhi
    Leukemia 30 (8), 1803 , 2016
    2016
    Citations: 38
  • Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia
    V Patel, MJ Keating, WG Wierda, V Gandhi
    Leukemia & lymphoma 57 (6), 1494-1497 , 2016
    2016
    Citations: 20
  • Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma
    A Sarkar, K Balakrishnan, J Chen, V Patel, SS Neelapu, JS McMurray, ...
    Oncotarget 7 (3), 3461 , 2016
    2016
    Citations: 9
  • A mechanistic rationale for testing the combination of duvelisib (IPI-145) and venetoclax (ABT-199) in chronic lymphocytic leukemia
    V Patel, K Balakrishnan, M Douglas, T Tibbitts, J Kutok, R Guerrieri, ...
    LEUKEMIA & LYMPHOMA 56, 109-110 , 2015
    2015
  • Elevated level of BCL-2 is the primary target for inhibition during duvelisib (IPI-145) therapy: ABT-199 neutralizes the resistance mechanism in chronic lymphocytic leukemia
    VM Patel, K Balakrishnan, R Guerrieri, W Wierda, S O'Brien, V Gandhi
    Cancer Research 75 (15 Supplement), 2657-2657 , 2015
    2015
    Citations: 3
  • Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells
    V Patel, K Balakrishnan, MJ Keating, WG Wierda, V Gandhi
    Blood 125 (7), 1126-1136 , 2015
    2015
    Citations: 39
  • Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia
    V Patel, LS Chen, WG Wierda, K Balakrishnan, V Gandhi
    Leukemia & lymphoma 55 (4), 899-910 , 2014
    2014
    Citations: 33
  • Investigating apoptosis pathway in chronic lymphocytic leukemia: stromal influence and therapeutic activation
    VM Patel
    2013
    Citations: 2
  • Impact of bone marrow microenvironment on mRNA expression of genes in the apoptotic pathway in CLL cells
    VM Patel, LS Chen, WG Wierda, K Balakrishnan, V Gandhi
    Cancer Research 72 (8 Supplement), 1490-1490 , 2012
    2012
    Citations: 1

MOST CITED SCHOLAR PUBLICATIONS

  • Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells
    V Patel, K Balakrishnan, E Bibikova, M Ayres, MJ Keating, WG Wierda, ...
    Clinical Cancer Research 23 (14), 3734-3743 , 2017
    2017
    Citations: 181
  • Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199)
    VM Patel, K Balakrishnan, M Douglas, T Tibbitts, EY Xu, JL Kutok, ...
    Leukemia 31 (9), 1872 , 2017
    2017
    Citations: 84
  • Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy
    VK Patel, B Lamothe, ML Ayres, J Gay, JP Cheung, K Balakrishnan, ...
    Leukemia 32 (4), 920 , 2018
    2018
    Citations: 42
  • Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells
    V Patel, K Balakrishnan, MJ Keating, WG Wierda, V Gandhi
    Blood 125 (7), 1126-1136 , 2015
    2015
    Citations: 39
  • Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes
    F Cervantes-Gomez, VK Patel, P Bose, MJ Keating, V Gandhi
    Leukemia 30 (8), 1803 , 2016
    2016
    Citations: 38
  • Impact of bone marrow stromal cells on Bcl-2 family members in chronic lymphocytic leukemia
    V Patel, LS Chen, WG Wierda, K Balakrishnan, V Gandhi
    Leukemia & lymphoma 55 (4), 899-910 , 2014
    2014
    Citations: 33
  • Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia
    V Patel, MJ Keating, WG Wierda, V Gandhi
    Leukemia & lymphoma 57 (6), 1494-1497 , 2016
    2016
    Citations: 20
  • Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma
    A Sarkar, K Balakrishnan, J Chen, V Patel, SS Neelapu, JS McMurray, ...
    Oncotarget 7 (3), 3461 , 2016
    2016
    Citations: 9
  • Elevated level of BCL-2 is the primary target for inhibition during duvelisib (IPI-145) therapy: ABT-199 neutralizes the resistance mechanism in chronic lymphocytic leukemia
    VM Patel, K Balakrishnan, R Guerrieri, W Wierda, S O'Brien, V Gandhi
    Cancer Research 75 (15 Supplement), 2657-2657 , 2015
    2015
    Citations: 3
  • Investigating apoptosis pathway in chronic lymphocytic leukemia: stromal influence and therapeutic activation
    VM Patel
    2013
    Citations: 2
  • Impact of bone marrow microenvironment on mRNA expression of genes in the apoptotic pathway in CLL cells
    VM Patel, LS Chen, WG Wierda, K Balakrishnan, V Gandhi
    Cancer Research 72 (8 Supplement), 1490-1490 , 2012
    2012
    Citations: 1
  • A mechanistic rationale for testing the combination of duvelisib (IPI-145) and venetoclax (ABT-199) in chronic lymphocytic leukemia
    V Patel, K Balakrishnan, M Douglas, T Tibbitts, J Kutok, R Guerrieri, ...
    LEUKEMIA & LYMPHOMA 56, 109-110 , 2015
    2015